167 related articles for article (PubMed ID: 10961606)
1. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Seminari E; Maggiolo F; Villani P; Suter F; Pan A; Regazzi MB; Paolucci S; Baldanti F; Tinelli C; Maserati R
J Acquir Immune Defic Syndr; 1999 Dec; 22(5):453-60. PubMed ID: 10961606
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Regazzi MB; Villani P; Maserati R; Seminari E; Pan A; LoCaputo F; Gambarana E; Fiocchi C
J Antimicrob Chemother; 2000 Mar; 45(3):343-7. PubMed ID: 10702554
[TBL] [Abstract][Full Text] [Related]
3. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
[TBL] [Abstract][Full Text] [Related]
5. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
[No Abstract] [Full Text] [Related]
6. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
8. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
10. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
12. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
13. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
15. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
[TBL] [Abstract][Full Text] [Related]
16. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Trabattoni D; Lo Caputo S; Biasin M; Seminari E; Di Pietro M; Ravasi G; Mazzotta F; Maserati R; Clerici M
Clin Diagn Lab Immunol; 2002 Sep; 9(5):1114-8. PubMed ID: 12204968
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Smith PF; Robbins GK; Shafer RW; Wu H; Yu S; Hirsch MS; Merigan TC; Park JG; Forrest A; Fischl MA; Morse GD;
Antimicrob Agents Chemother; 2005 Aug; 49(8):3558-61. PubMed ID: 16048984
[TBL] [Abstract][Full Text] [Related]
18. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
